An Open-label Study in Healthy Subjects to Assess the Effect of Once-daily Multiple Dosing of AKB-6548 on the Pharmacokinetics of the CYP2C9 Substrate Celecoxib

Trial Profile

An Open-label Study in Healthy Subjects to Assess the Effect of Once-daily Multiple Dosing of AKB-6548 on the Pharmacokinetics of the CYP2C9 Substrate Celecoxib

Completed
Phase of Trial: Phase I

Latest Information Update: 23 May 2016

At a glance

  • Drugs Celecoxib (Primary) ; Vadadustat (Primary)
  • Indications Anaemia
  • Focus Pharmacokinetics
  • Sponsors Akebia Therapeutics
  • Most Recent Events

    • 23 May 2016 According to an Akebia Therapeutics media release, results of this trial were presented at the 53rd European Renal Association-European Dialysis and Transplant Association (ERA-EDTA) Congress.
    • 23 May 2016 Results (n=12) published in an Akebia Therapeutics media release.
    • 21 Oct 2015 Status changed from not yet recruiting to completed as reported by ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top